Dale E. Johnson
At UC Berkeley Dr. Johnson’s research is focused on computational systems toxicology and network pharmacology utilizing computational methodology to analyze chemical-biological-gene-disease interactions, model structure activity relationships, and analyze perturbations in systems biology pathways. These technologies are being applied to solve problems in environmental toxicity, side effects associated with human therapeutics, and interactions between Traditional Chinese Medicines and Western therapeutics.
Dr. Johnson has extensive experience in drug research and development where has been directly involved in the advancement of over 100 compounds from discovery into clinical development of which sixteen have become marketed health care medicinal products and vaccines in the US, Canada, Europe, and Japan. Through his affiliation with Emiliem, Inc. his research involved novel compounds that are multi-kinase inhibitors. With Elara Bioscience his work involves the creation of enterprise applications for information used in chemical safety applications, green chemistry initiatives, particularly in the chemical design process, and the interactions between herbal medicines and Western therapeutics. Elara Bioscience has established the Elarabio Molecular Toxicology Internships at UC Berkeley, where student interns are creating and applying software tools, website-based applications, and social media into on-line and secure transfer information tools and systems.
Dr. Johnson is a member of the Chemical Safety for Sustainability Subcommittee of the US EPA Board of Scientific Counselors. Previously, he was a member of the initial Green Ribbon Science Panel for California EPA Department of Toxic Substances Control.
Most Recent Publications
Lindsay C. Burrage, Qin Sun, Sarah H. Elsea, Ming-Ming Jiang, Sandesh C.S. Nagamani, Arthur E. Frankel, Evertt Stone, Susan E. Alters, Dale E. Johnson, Scott W. Rowlinson, George Georgiou, Brendan H. Lee (2015) Human recombinant arginase enzyme reduces plasma arginase in mouse models of arginase deficiency. Human Molecular Genetics, 24(22) 6417-6427
Megan Schwarzman, Janet Ackerman, Shanaz Dairkee, Suzanne Fenton, Dale Johnson, Kathleen Navarro, Gwendolyn Osborne, Ruthann Rudel, Gina Solomon, Lauren Zeise, Sarah Janssen (2015) Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation. Environ Health Perspectives. 123(12) 1255-1264.
Dale E. Johnson (2014) Fast-tracking an orphan drug indication within a broader development project. Expert Opinion Orphan Drugs 2(2) 107-111
Dana Felker, Alexandra Lynn, Sue Wang, Dale Johnson (2014) Evidence for a Potential Protective Effect of Carnitine-Pantothenic Acid Co-treatment on Valproic Acid-Induced Hepatotoxicity. Expert Rev Clin Pharmacol 7 (2) 211-218
Dale E Johnson (2013) Fusion of nonclinical and clinical data to predict human drug safety. Exp Rev Clin Pharmacol. 6(2) 185-195. Doi:10.1586/ecp.13.3
Dale E. Johnson and Grace L. Anderson (2013) Green Chemistry and Toxicology. Chapter 11 in "Green Chemistry and Engineering: A Pathway to Sustainability". Editors: M. Abraham and A.E. Marteel-Parrish. John Wiley & Sons, New York. Pp 325-353
Harmony Larson, Elena Chan, Sucha Sudarsanam, and Dale E. Johnson. (2012) Biomarkers. In Computational Toxicology Vol II. Chapter 11, Methods in Molecular Biology, Eds. Reisfeld B and Mayeno A.Humana Press, Springer Science, NY, NY. pp. 253-273.
Dale E. Johnson and Sucha Sudarsanam (2012) Molecular challenges in frontloading toxicity testing of anti-cancer drugs in drug discovery. Encyclopedia of Drug Metabolism and Interactions. Chapter 3. Pp-1-20, Ed. Lyubinov AV, John Wiley & Sons, New York. DOI:10.1002/9780470921920.edm048
Dale E Johnson (2012) Estimating human cancer risk from rodent carcinogenicity studies: The changing paradigm for pharmaceuticals. J Drug Metab Toxicol. 3 (6) Open Access. http://dx.doi.org/10.4172/2157-7609.1000e114
Dale E. Johnson (2012) Predicting drug safety: Next generation solutions. J Drug Metab Toxicol. 3 (2) Open Access http://dx.doi.org/10.4172/2157-7609.1000e106
Johnson Dale E, Srinivasan Subha, Bingham Jonathan, and Sudarsanam Sucha. (2012) Translational biology approach to identify causative factors for rare toxicities in humans and animals. Curr Drug Discov Technol . 9(1) 77-80.
Dale E. Johnson (2010) Biotherapeutic first in human dose selection: making use of preclinical markers . Expert Rev Clin Pharmacol. 3(2) 231-242
Johnson DE, Smith DA, and Park BK (2010) Immunomodulatory Therapies and the risk of Opportunistic Infections. Current Opinion Drug Disc Develop . 13 (1) 20-22
Elena Chan, Marisela Tan, Jianni Xin, Sucha Sudarsanam, and Dale E. Johnson (2010) Interactions between Traditional Chinese Medicines and Western Therapeutics. Current Opinion Drug Disc Develop. 13(1) 58-73
Sucha Sudarsanam and Dale E. Johnson (2010) Functional consequences of mTOR inhibition. Current Opinion Drug Disc Develop . 13(1) 39-48
Honors and Awards
Dr. Johnson received his Ph.D. degree in Toxicology from the University of Michigan where he was an AFPE Graduate Fellow and a Penick Memorial Fellow. He is a Board Certified Toxicologist, American Board of Toxicology. Prior to his Ph.D. work, he received B.S. and Pharm.D. degrees from the University of Michigan College of Pharmacy and completed a residency at UM Medical Center receiving the Squibb National Resident of the Year Award for his work on adverse drug reactions. Dr. Johnson is the co-inventor of seven issued U.S. patents on integrin biology and anti-angiogenesis.